Men represent only 10% of cases however, the clinicohistologic characteristics of the disease are same in both sexes. This disease is commonly observed in women. Journal of Cosmetic Dermatology, 22(6), 1780–1785.Melasma is a common acquired dermatitis of light to dark brown macules and patches involving the sun-exposed areas of the face and neck. Efficacy and safety of Politranexamide® liposomal emulsion on facial melasma: A comparative study. As further research and development continue, this breakthrough treatment is expected to transform the lives of countless individuals affected by this challenging condition. However, with the emergence of Politranexamide liposomal emulsion as a potent solution, the medical community stands poised to usher in a new era of effective melasma management. Melasma has long been a complex dermatological concern, and finding suitable remedies has remained elusive.
By demonstrating its potential to address the challenges posed by melasma, Politranexamide® offers renewed hope to patients and healthcare professionals alike. The study's outcomes firmly establish Politranexamide as a superior treatment to the competitor formulation used in this investigation. These compelling results pave the way for adopting Politranexamide® liposomal emulsion as an efficacious and safe therapeutic option for individuals struggling with melasma. Both treatment groups experienced an improvement in the average level of melanin measured by the Antera imaging system.The intergroup comparison demonstrated a significantly greater improvement in melasma among patients treated with Politranexamide® at both 6 weeks (p = 0.055009) and 12 weeks (p = 0.032942) of follow-up.Both treatment groups exhibited a noteworthy decrease in MASI scores as early as 6 weeks into the follow-up period (p = 0.00096 for SAMPLE A and p = 0.0049 for SAMPLE B), which continued to improve until the end of the treatment (p = 0.0006 for SAMPLE A and p = 0.00039 for SAMPLE B).
At baseline, the mean MASI score was 10.93 ± 7 in the Politranexamide® group (SAMPLE A) and 9.34 ± 6.29 in the competitor group (SAMPLE B).
Disease severity was assessed using the Melasma Area Severity Index (MASI) at baseline and after 6 and 12 weeks of therapy. The prospective, randomised, single-blind study was conducted by Valeria Manfreda and colleagues at Dermatology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy on a cohort of 26 patients affected by facial melasma, aimed to compare the efficacy and tolerability of Politranexamide® (SAMPLE A) with a competitor formulation based on acetylglucosamine, ethyl linoleate, and phenyl ethyl resorcinol (SAMPLE B).
#MELASMA EMULSION SKIN#
Melasma is a challenging condition characterized by localized, chronic acquired hypermelanosis of the skin that has long posed difficulties finding effective treatment options The study was published in the Journal Of Cosmetic Dermatology on 31 January 2023. Italy: A recent study has shed light on melasma treatment highlighting the exceptional potential of Politranexamide liposomal emulsion in combating this condition. CDSCO (Central Drugs Standard Control Organisation) News.
0 kommentar(er)
